Protalix BioTherapeutics Announces Final Dosing of Last Patient in Phase II Clinical Trial of OPRX-106 in Patients with Ulcerative Colitis . CARMIEL, Israel, Feb. 15, 2018 Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), announced today the final dosing of the last patient in the Company's phase II clinical trial evaluating OPRX-106, the Company's oral antiTNF product candidate, in patients with ulcerative colitis (UC). OPRX-106 is the Company's proprietary plant cell-expressed recombinant human tumor necrosis factor receptor II fused to an IgG1 Fc domain (TNFRII-Fc). The Company expects to report top-line results from this study by the end of March 2018. "Given the positive preliminary data we have reported already, we are excited to be nearing the completion of this study," said Mr. Moshe Manor, Protalix's President and Chief Executive Officer. Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx(R).
What is My own opinion about this stock ?
the stock for sure is very attractive as possible cheap entry between 0.58 and 0.64 level .My rate is strong hold /Buy rate my price target for the next 30 days is 1 $ . There is always a risk with any stock trade .
Important note : I am uncertified technical chart analysis and I do not have any insider trading or position at this stock, you own your decision to buy, hold or sell this stock.
How I became a successful trader this is the simple answer visit this if you interested to be too https://tinyurl.com/y8pq9496 .
Share on Facebook
Share on Twitter
I'm busy working on my blog posts. Watch this space!